Member access

4-Traders Homepage  >  Shares  >  Euronext Paris  >  SANOFI    SAN   FR0000120578


SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 

Sanofi: Tests Show Zaltrap Improves Colorectal Cancer Survival Rate

10/08/2012 | 01:44am US/Eastern

French drug company Sanofi SA (>> SANOFI) Monday said results from the pivotal Phase III Velour study evaluating Zaltrap showed improvement in overall survival rate to colorectal cancer.


- Sanofi said the Journal of Clinical Oncology published the results of the study evaluating Zaltrap effects.

- In the Velour trial evaluating metastatic colorectal cancer patients previously treated with an oxaliplatin-containing regimen, Zaltrap in combination with the Folfiri chemotherapy regimen (5-fluorouracil, leucovorin, irinotecan) showed a statistically significant improvement in overall survival, progression-free survival, and the overall tumor response rate versus placebo plus Folfiri.

- The Velour data supported the regulatory approval of Zaltrap by the U.S. Food and Drug Administration (FDA) on August 3, 2012 after a Priority Review.

- Zaltrap is under review at the European Medicines Agency and other regulatory agencies worldwide, Sanofi says.

-Write to Inti Landauro at

Subscribe to WSJ:

Stocks mentioned in the article : SANOFI
Recommend :
React to this article
Latest news on SANOFI
2h ago GENZYME : Investigators from Genzyme Corporation Zero in on Immunoglobulins
4h ago Novartis-GSK asset swap offers template for pharma and beyond
5h ago SANOFI : Pitt CVR and Sanofi Pasteur collaborate to assess the effectiveness of ..
1d agoDJGlaxo Exits Cancer Drugs
1d ago SANOFI : Glenmark Pharmaceuticals through its Swiss Subsidiary receives USD 5 Mn..
1d ago SANOFI INDIA : : India appoints N. Rajaram As Country Head and General Manager -..
2d ago Sanofi india appoints n rajaram as country head
5d ago SANOFI : Chattem Assigned Patent
5d ago SANOFI : Penn Vet Ophthalmologists Offer Free Eye Exams for Service Dogs
5d ago GLENMARK PHARMACEUTICALS : Gets $5 million from sanofi
Duration : Period :
SANOFI Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Income Statement Evolution
SANOFI : Income Statement Evolution
More Financials
Dynamic quotes